CD4 and CD4+/CD56+ hematodermic neoplasm: Compared to non-cutaneous BPDCN, cutaneous BPDCN was associated with an older median age at onset (72 vs 45 years) and positivity for CD4, CD123, and 2-3 pDC markers (89 vs 50%).